Comparison of simultaneous 18F-2-[18F] FDG PET/MR and PET/CT in the follow-up of patients with differentiated thyroid cancer-Reference-Cited by-同舟云学术

Comparison of simultaneous 18F-2-[18F] FDG PET/MR and PET/CT in the follow-up of patients with differentiated thyroid cancer

Published:2020-06-30 Issue:13 Volume:47 Page:3066-3073
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Klain Michele,Nappi Carmela,Nicolai Emanuele,Romeo Valeria,Piscopo Leandra,Giordano Alessia,Gaudieri Valeria,Zampella Emilia,Pace Leonardo,Carlo Cavaliere,Salvatore Marco,Schlumberger Martin,Cuocolo Alberto^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-020-04938-0.pdf

Reference23 articles.

1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.

2. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F] Fluoro-2-Deoxy-D-glucose positron emission tomography. J Clin Endocrinol Metab. 2006;91:498–505.

3. Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M, et al. Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptake) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer. 2011;18:159–69.

4. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, et al. Post-operative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT): an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid. 2015;25:437–44.

5. Pace L, Klain M, Tagliabue L, Storto G. The current and evolving role of FDG-PET/CT in personalized iodine 131 therapy of differentiated thyroid cancer. Clin Transl Imaging. 2017;5:533–44.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PET/RM nel carcinoma differenziato della tiroide: presente e futuro;L'Endocrinologo;2024-08

2. Tumor Burden of Iodine-Avid Bone Metastatic Thyroid Cancer Identified via 18F-Sodium Fluoride PET/CT Imaging;Journal of Clinical Medicine;2024-01-19

3. PET-CT bei differenziertem Schilddrüsenkrebs;Nuklearmedizin bei endokrinen Erkrankungen;2024

4. [18F]FET PET/MR and machine learning in the evaluation of glioma;European Journal of Nuclear Medicine and Molecular Imaging;2023-11-13

5. The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer;Journal of Translational Medicine;2023-10-18